Fig. 4: Identification of SFRS2 as a PANDAR-targeting protein in ovarian cancer cellular nucleus.

a Schematic of prediction and consensus experiments of PANDAR-binding protein. b Prediction of PANDAR cellular location using lncLocator Database (http://www.csbio.sjtu.edu.cn/bioinf/lncLocator/). c Logo of matching sequence or motif between PANDAR and SFRS2 downloaded from RBPDB database (http://rbpdb.ccbr.utoronto.ca/experiments.php?exp_id=791). d QRT-PCR assay of PANDAR expression in the nucleus and cytoplasm from A2780 and A2780-DDP cells after a 24 h treatment of 20 μM cisplatin. e Cellular extracts from A2780 and HO-8910PM cells treated with 20 μM cisplatin for 24 h, and RNA immunoprecipitation (RIP) assay showing immunoprecipitation (IP) with control IgG or SFRS2 antibody by western blotting (left) and qRT-PCR (right) performed with isolated RNA and the following reverse transcription (RT) using primers for lncRNA PANDAR. f Fluorescence in situ hybridization (FISH) assay of PANDAR RNA (green) in A2780 cells distributes in discrete foci through the nucleus and cytoplasm at the beginning of treatment with 20 μM cisplatin (0 h). The foci increased and focused in the nucleus after cisplatin treatment for 12 and 24 h. Co-localization of SFRS2 protein (red) in A2780 cells via immunocytochemistry performed with SFRS2 antibodies and showed an increasing discreted foci through the nucleus after cisplatin treatment (12 h, 24 h), and is not detected in cytoplasm. Scale bar: 2 μm. g Kaplan–Meier Plotter of overall survival (OS) regarding SFRS2 (200753_x_at) in ovarian cancer patients (http://kmplot.com/analysis/index.php?p=service&start=1). Kaplan–Meier Plotter of SFRS2 (200753_x_at) overall survival (OS) in ovarian cancer patients with (right) or without (left) p53 mutation. Control groups are normalized to 1. Data presents the mean ± S.D. **p < 0.01, ***p < 0.001, ****p < 0.0001, two-tailed Student’s t-test. n = 3 independent experiments